Keywords
Autosomal Dominant
tolvaptan
Renal Disease
Kidney Diseases
Cystic
hypertension
Renal Insufficiency
Chronic
How to Cite
Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common cause of inherited adult nephropathy and stage 5 chronic kidney disease of genetic origin, it is a heterogeneous disease with phenotypic variability in relation to progression. All measures aimed at slowing the progression of renal disease should be established.
Purpose: To generate evidence-based recommendations for the diagnosis, follow-up and treatment of patients with ADPKD, defining patients with rapid disease progression, guide general and specific treatment with the agent tolvaptan, establish recommendations for access to renal replacement therapies including transplantation, through an expert consensus.
Methodology: Based on the formulation of pragmatic research questions related to ADPKD, a search for evidence was conducted in Pubmed, Scopus and Ovid between January 2012 and July 2023. The articles were selected by means of a systematic review and through the modified Delphi consensus methodology. The Oxford scale was applied to quantify the level of evidence of the total selected scientific articles. All final recommendations were categorised by grade according to the NHS guidelines classification.
Results: A total of 18 recommendations were formulated for the diagnosis, treatment and follow-up of ADPKD. A panel of 10 thematic experts, a methodological expert and 2 external reviewers actively participated in the elaboration of the consensus.
Conclusions: The recommendations based on evidence and clinical expertise adapted to the Colombian context will allow standardised guidance at national and regional level, the diagnosis and treatment of patients with ADPKD and provide guidance on the use and application of tolvaptan.
References
Saini AK, Saini R, Singh S. Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects. Mol Med. 2020;26(1):128. https://doi.org/10.1186/s10020-020-00246-3
McEwan P, Bennett Wilton H, Ong ACM, Ørskov B, Sandford R, Scolari F, et al. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): The ADPKD Outcomes Model. BMC Nephrol. 2018;19(1):37. https://doi.org/10.1186/s12882-017-0804-2
Smith JD, Johnson AB. Best practices: care of patients with autosomal dominant polycystic kidney disease in BC’s Kidney Care Clinics. Journal of Nephrology. 2019;25(3):123-35. http://www.bcrenal.ca/resource-gallery/Documents/Best_Practices-Care_of_Patients_with_Autosomal_Dominant_Polycystic_Kidney_Disease_in_BC_Kidney_Care_Clinics.pdf
Ars E, Bernis C, Fraga G, Furlano M, Martínez V, Martins J, et al. Consensus document on autosomal dominant polycystic kindey disease from the Spanish Working Group on Inherited Kindey Diseases. Review 2020. Nefrología (Engl Ed). 2022;42(4):367-89. https://doi.org/10.1016/j.nefroe.2022.11.011
He WB, Xiao WJ, Tan YQ, Zhao XM, Li W, Zhang QJ, et al. Novel mutations of PKD genes in Chinese patients suffering from autosomal dominant polycystic kidney disease and seeking assisted reproduction. BMC Med Genet. 2018;19(1):186. https://doi.org/10.1186/s12881-018-0693-7
Oh YK, Park HC, Ryu H, Kim YC, Oh KH. Clinical and genetic characteristics of korean autosomal dominant polycystic kidney disease patients. Korean J Intern Med. 2021;36(4):767-79. https://doi.org/10.3904/kjim.2021.176
Wilson EM, Choi J, Torres VE, Somlo S, Besse W. Large deletions in GANAB and SEC63 explain 2 cases of polycystic kidney and liver disease. Kidney Int Rep. 2020;5(5):727-31. https://doi.org/10.1016%2Fj.ekir.2020.01.009
Camargo JT, González CA, Herrera L, Yomayusa-González N, Ibañez M, Valbuena-García AM, et al. Autosomal dominant polycystic kidney disease in Colombia. BMC Nephrol. 2023;24(1):211. https://doi.org/10.1186/s12882-023-03266-3
Fernandes Nunes AC, Milani V, Benck Porsch D, Bertolin Rossato L, Bastos Mattos C, Roisenberg I, et al. Frequency and clinical profile of patients with polycystic kidney disease in southern Brazil. Ren Fail. 2008;30(2):169-73. https://doi.org/10.1080/08860220701810265
Barnawi RA, Attar RZ, Alfaer SS, Safdar OY. Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptán as a new treatment. Int J Nephrol Renovasc Dis. 2018;11:53-67. https://doi.org/10.2147/ijnrd.s136359
Rastogi A, Ameen KM, Al-Baghdadi M, Shaffer K, Nobakht N, Kamgar M, et al. Autosomal dominant polycystic kidney disease: updated perspectives. Ther Clin Risk Manag. 2019;15:1041-52. https://doi.org/10.2147/tcrm.s196244
Radhakrishnan Y, Duriseti P, Chebib FT. Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options. Kidney Res Clin Pract. 2022;41(4):422-31. https://doi.org/10.23876/j.krcp.21.309
Harris PC, Torres VE. Polycystic kidney disease, autosomal dominant. En: Adam MP, Feldman J, Mirzaa GM, Pagon ra, Wallace SE, Amemiya A, editors. GeneReviews. Seattle, Estados Unidos: University of Washington; 2022. https://www.ncbi.nlm.nih.gov/books/NBK1246/
Vasileva VY, Sultanova RF, Sudarikova AV, Ilatovskaya DV. Insights into the molecular mechanisms of polycystic kidney diseases. Front Physiol. 2021;12:693130. https://doi.org/10.3389/fphys.2021.693130
Montaña A, Patiño N, Larrate C, Zambrano FA, Martínez J, Lozano H, et al. Actualización en enfermedad renal poliquística. Rev Fac Med. 2018;66(1):107-16. http://dx.doi.org/10.15446/revfacmed.v66n1.60760
Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, et al. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrol Dial Transplant. 2018;33(4):645-52. https://doi.org/10.1093/ndt/gfx188
Kashyap S, Hein KZ, Chini CC, Lika J, Warner GM, Bale LK, et al. Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis. JCI Insight. 2020;5(4):e135700. https://doi.org/10.1172/jci.insight.135700
Carullo N, Zicarelli MT, Casarella A, Nicotera R, Castagna A, Urso A, et al. Retarding progression of chronic kidney disease in autosomal dominant polycystic kidney disease with metformin and other therapies: an update of new insights. Int J Gen Med. 2021;14:5993-6000. https://doi.org/10.2147/ijgm.s305491
Bitarafan F, Garshasbi M. Molecular genetic analysis of polycystic kidney disease 1 and polycystic kidney disease 2 mutations in pedigrees with autosomal dominant polycystic kidney disease. J Res Med Sci. 2019;24:44. https://doi.org/10.4103/jrms.jrms_835_18
Lai S, Mangiulli M, Perrotta AM, Di Lazzaro Giraldi G, Testorio M, Rosato E, et al. Reduction in heart rate variability in autosomal dominant polycystic kidney disease. Kidney Blood Press Res. 2019;44(5):1142-8. https://doi.org/10.1159/000502419
Kuo IY, Chapman AB. Polycystins, ADPKD, and Cardiovascular Disease. Kidney Int Rep. 2019;5(4):396-406. https://doi.org/10.1016/j.ekir.2019.12.007
Mei CL, Xue C, Yu SQ, Dai B, Chen JH, Li Y, et al. Executive summary: clinical practice guideline for autosomal dominant polycystic kidney disease in China. Kidney Dis. 2020;6(3):144-9. https://doi.org/10.1159/000506288
Fukasawa H, Kaneko M, Niwa H, Yasuda H, Kumagai H, Furuya R. Carbohydrate antigen 19-9 is significantly elevated in autosomal dominant polycystic kidney disease. Nephrology. 2018;23(3):210-6. https://doi.org/10.1111/nep.12988
Van Laecke S, Van Biesen W. Novel non-cystic features of polycystic kidney disease: Having new eyes or seeking new landscapes. Clin Kidney J. 2021;14(3):746-55. https://doi.org/10.1093/ckj/sfaa138
Yang B, Wang Q, Wang R, Xu T. Clinical manifestation, management and prognosis of acute myocardial infarction in autosomal dominant polycystic kidney disease. Kidney Blood Press Res. 2018;43(6):1806-12. https://doi.org/10.1159/000495638
Ecder T, Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol. 2001;12(1):194-200. https://doi.org/10.1681/asn.v121194
Kalatharan V, Welk B, Nash DM, Dixon SN, Slater J, Pei Y, et al. Risk of hospital encounters with kidney stones in autosomal dominant polycystic kidney disease: a cohort study. Can J Kidney Health Dis. 2021;8:20543581211000227. https://doi.org/10.1177/20543581211000227
Van Laecke S, Kerre T, Nagler EV, Maes B, Caluwe R, Schepers E, et al. Hereditary polycystic kidney disease is characterized by lymphopenia across all stages of kidney dysfunction: an observational study. Nephrol Dial Transplant. 2018;33(3):489-96. https://doi.org/10.1093/ndt/gfx040
Banerjee A, Chandna S, Jayasena D, Farrington K. Leucopenia in adult polycystic kidney disease patients on haemodialysis. Nephron. 2002;91(1):175-6. https://doi.org/10.1159/000057625
Férnandez A, Hortal L, Rodríguez JC, Vega N, Plaza C, Palop L. Anemia in dialysis: its relation to acquired cystic kidney disease and serum levels of erythropoietin. Am J Nephrol. 1991;11(1):12-5. https://doi.org/10.1159/000168265
Eckardt KU, Möllmann M, Neumann R, Brunkhorst R, Burger HU, Lonnemann G, et al. Erythropoietin in polycystic kidneys. J Clin Invest. 1989;84(4):1160-6. https://doi.org/10.1172/jci114280
Yu TM, Chuang YW, Yu MC, Chen CH, Yang CK, Huang ST, et al. Risk of cancer in patients with polycystic kidney disease: a propensity-score matched analysis of a nationwide, population-based cohort study. Lancet Oncol. 2016;17(10):1419-25. https://doi.org/10.1016/s1470-2045(16)30250-9
Sun K, Xu D, Mei C. The association between autosomal dominant polycystic kidney disease and cancer. Int Urol Nephrol. 2019;51(1):93-100. https://doi.org/10.1007/s11255-018-1951-5
Moua T, Zand L, Hartman RP, Hartman TE, Qin D, Peikert T, et al. Radiologic and clinical bronchiectasis associated with autosomal dominant polycystic kidney disease. PLoS One. 2014;9(4):e93674. https://doi.org/10.1371/journal.pone.0093674
Caillard S, Eprinchard L, Perrin P, Braun L, Heibel F, Moreau F, et al. Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test. Transplantation. 2011;91(7):757-64. https://doi.org/10.1097/tp.0b013e31820f0877
Cheungpasitporn W, Thongprayoon C, Vijayvargiya P, Anthanont P, Erickson SB. The risk for new-onset diabetes mellitus after kidney transplantation in patients with autosomal dominant polycystic kidney disease: a systematic review and meta-analysis. Can J Diabetes. 2016;40(6):521-8. https://doi.org/10.1016/j.jcjd.2016.03.001
Evenepoel P, Claes K, Cavalier E, Meijers B, Stenvinkel P, Behets G, et al. A distinct bone phenotype in ADPKD patients with end-stage renal disease. Kidney Int. 2019;95(2):412-9. https://doi.org/10.1016/j.kint.2018.09.018
Nowak KL, Murray K, You Z, Gitomer B, Brosnahan G, Abebe KZ, et al. Pain and obesity in autosomal dominant polycystic kidney disease: a post hoc analysis of the halt progression of polycystic kidney disease (HALT-PKD) studies. Kidney Med. 2021;3(4):536-545.e1. https://doi.org/10.1016/j.xkme.2021.03.004
Pijl JP, Glaudemans AWJM, Slart RHJA, Kwee TC. 18F-FDG PET/CT in Autosomal Dominant Polycystic Kidney Disease Patients with Suspected Cyst Infection. J Nucl Med. 2018;59(11):1734-41. https://doi.org/10.2967/jnumed.117.199448
Masui K, Wajima D, Aketa S. Characteristics of the ruptured intracranial cerebral aneurysms in patients with autosomal dominant polycystic kidney disease (ADPKD) and review of literature. Interdiscip Neurosurg. 2020;22. http://dx.doi.org/10.1016/j.inat.2020.100846
University of Oxford. OCEBM Levels of Evidence. Centre for evidence-Based Medicine; 2023 [citado 2023 abr. 22]. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence
Molnar AO, Barua M, Konvalinka A, Schick-Makaroff K. Patient engagement in kidney research: opportunities and challenges ahead. Can J Kidney Health Dis. 2017;4:2054358117740583. https://doi.org/10.1177/2054358117740583
Soroka S, Alam A, Bevilacqua M, Girard LP, Komenda P, Loertscher R, et al. Updated Canadian expert consensus on assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease. Can J Kidney Health Dis. 2018;5:2054358118801589. https://doi.org/10.1177/2054358118801589
Soroka S, Alam A, Bevilacqua M, Girard LP, Komenda P, Loertscher R, et al. Assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease: a canadian expert consensus. Can J Kidney Health Dis. 2017;4:2054358117695784. https://doi.org/10.1177/2054358117695784
Pei Y, Hwang YH, Conklin J, Sundsbak JL, Heyer CM, Chan W, et al. Imaging-based diagnosis of autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2015;26(3):746-53. https://doi.org/10.1681/asn.2014030297
Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20(1):205-12. https://doi.org/10.1681/asn.2008050507
Ars E, Bernis C, Fraga G, Martínez V, Martins J, Ortiz A, et al. Spanish guidelines for the management of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014;29(supl. 4):iv95-105.
Audrézet MP, Cornec-Le Gall E, Chen JM, Redon S, Quéré I, Creff J, et al. Autosomal dominant polycystic kidney disease: comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patients. Hum Mutat. 2012;33(8):1239-50. https://doi.org/10.1002/humu.22103
Torra R, Badenas C, Darnell A, Nicolau C, Volpini V, Revert L, et al. Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2. J Am Soc Nephrol. 1996;7(10):2142-51. https://doi.org/10.1681/asn.v7102142
Consugar MB, Wong WC, Lundquist PA, Rossetti S, Kubly VJ, Walker DL, et al. Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int. 2008;74(11):1468-79. https://doi.org/10.1038/ki.2008.485
Bullich G, Domingo-Gallego A, Vargas I, Ruiz P, Lorente-Grandoso L, Furlano M, et al. A kidney-disease gene panel allows a comprehensive genetic diagnosis of cystic and glomerular inherited kidney diseases. Kidney Int. 2018;94(2):363-71. https://doi.org/10.1016/j.kint.2018.02.027
Vujic M, Heyer CM, Ars E, Hopp K, Markoff A, Orndal C, et al. Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. J Am Soc Nephrol. 2010;21(7):1097-102. https://doi.org/10.1681/asn.2009101070
Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, et al. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int. 2009;75(8):848-55. https://doi.org/10.1038/ki.2008.686
Cornec-Le Gall E, Audrézet MP, Rousseau A, Hourmant M, Renaudineau E, Charasse C, et al. The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016;27(3):942-51. https://doi.org/10.1681/asn.2015010016
Sekine A, Hidaka S, Moriyama T, Shikida Y, Shimazu K, Ishikawa E, et al. Cystic kidney diseases that require a differential diagnosis from autosomal dominant polycystic kidney disease (ADPKD). J Clin Med. 2022;11(21):6528. https://doi.org/10.3390%2Fjcm11216528
Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, et al. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol. 2014;25(11):2399-418. https://doi.org/10.1681/asn.2013111184
Reiterová J, Tesa? V. Autosomal dominant polycystic kidney disease: from pathophysiology of cystogenesis to advances in the treatment. Int J Mol Sci. 2022;23(6):3317. https://doi.org/10.3390/ijms23063317
Cornec-Le Gall E, Olson RJ, Besse W, Heyer CM, Gainullin VG, Smith JM, et al. Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. Am J Hum Genet. 2018;102(5):832-44. https://doi.org/10.1016/j.ajhg.2018.03.013
Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptán. J Am Soc Nephrol. 2018;29(10):2458-70. https://doi.org/10.1681/asn.2018060590
Cornec-Le Gall E, Audrézet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013;24(6):1006-13. https://doi.org/10.1681/asn.2012070650
Magistroni R, He N, Wang K, Andrew R, Johnson A, Gabow P, et al. Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2003;14(5):1164-74. https://doi.org/10.1097/01.asn.0000061774.90975.25
Fick-Brosnahan GM, Tran ZV, Johnson AM, Strain JD, Gabow PA. Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int. 2001;59(5):1654-1662. https://doi.org/10.1046/j.1523-1755.2001.0590051654.x
Pei Y, Lan Z, Wang K, Garcia-Gonzalez M, He N, Dicks E, et al. A missense mutation in PKD1 attenuates the severity of renal disease. Kidney Int. 2012;81(4):412-7. https://doi.org/10.1038/ki.2011.370
Pérez-Oller L, Torra R, Badenas C, Milà M, Darnell A. Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1999;34(2):273-8. https://doi.org/10.1016/s0272-6386(99)70355-0
Casteleijn NF, Zittema D, Bakker SJL, Boertien WE, Gaillard CA, Meijer E, et al. Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis? Am J Nephrol. 2015;41(3):248-56. https://doi.org/10.1159/000382081
Segarra-Medrano A, Martin M, Agraz I, Vilaprinyó M, Chamoun B, Jatem E, et al. Association between urinary biomarkers and disease progression in adults with autosomal dominant polycystic kidney disease. Clin Kidney J. 2020;13(4):607-12. https://doi.org/10.1093/ckj/sfz105
Hallows KR, Althouse AD, Li H, Saitta B, Abebe KZ, Bae KT, et al. Association of baseline urinary metabolic biomarkers with ADPKD severity in TAME-PKD clinical trial participants. Kidney360. 2021;2(5):795-808. https://doi.org/10.34067/kid.0005962020
Liebau MC, Mekahli D, Perrone R, Soyfer B, Fedeles S. Polycystic kidney disease drug development: a conference report. Kidney Med. 2022;5(3):100596. https://doi.org/10.1016/j.xkme.2022.100596
Messchendorp AL, Meijer E, Visser FW, Engels GE, Kappert P, Losekoot M, et al. Rapid progression of autosomal dominant polycystic kidney disease: urinary biomarkers as predictors. Am J Nephrol. 2019;50(5):375-85. https://doi.org/10.1159/000502999
Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF, et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6(3):640-7. https://doi.org/10.2215/cjn.03250410
Helal I, McFann K, Reed B, Yan XD, Schrier RW, Fick-Brosnahan GM. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2013;28(2):380-5. https://doi.org/10.1093/ndt/gfs417
Brosnahan GM, You Z, Wang W, Gitomer BY, Chonchol M. Serum uric acid and progression of autosomal dominant polycystic kidney disease: results from the HALT PKD Trials. Curr Hypertens Rev. 2021;17(3):228-37. https://doi.org/10.2174/1573402116666200817113125
Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160-72. https://doi.org/10.1681/asn.2013101138
Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015;88(1):17-27. https://doi.org/10.1038/ki.2015.59
Grantham JJ, Torres VE. The importance of total kidney volume in evaluating progression of polycystic kidney disease. Nat Rev Nephrol. 2016;12(11):667-77. https://doi.org/10.1038/nrneph.2016.135
Müller RU, Messchendorp AL, Birn H, Capasso G, Cornec-Le Gall E, Devuyst O, et al. An update on the use of tolvaptán for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrol Dial Transplant. 2022;37(5):825-39. https://doi.org/10.1093/ndt/gfab312
Horie S, Mochizuki T, Muto S, Hanaoka K, Fukushima Y, Narita I, et al. Evidence-based clinical practice guidelines for polycystic kidney disease 2014. Clin Exp Nephrol. 2016;20(4):493-509. https://doi.org/10.1007/s10157-015-1219-7
Girardat-Rotar L, Braun J, Puhan MA, Abraham AG, Serra AL. Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients. BMC Nephrol. 2017;18(1):241. https://doi.org/10.1186/s12882-017-0654-y
Rangan GK, Alexander SI, Campbell KL, Dexter MA, Lee VW, Lopez-Vargas P, et al. KHA-CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease. Nephrology. 2016;21(8):705-16. https://doi.org/10.1111/nep.12658
Gansevoort RT, Meijer E, Chapman AB, Czerwiec FS, Devuyst O, Grantham JJ, et al. Albuminuria and tolvaptán in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrol Dial Transplant. 2016;31(11):1887-94. https://doi.org/10.1093/ndt/gfv422
Nobakht N, Hanna RM, Al-Baghdadi M, Ameen KM, Arman F, Nobahkt E, et al. Advances in autosomal dominant polycystic kidney disease: a clinical review. Kidney Med. 2020;2(2):196-208. https://doi.org/10.1016/j.xkme.2019.11.009
Quiroga B, Torra R. Dietary aspects and drug-related side effects in autosomal dominant polycystic kidney disease progression. Nutrients. 2022;14(21):4651. https://doi.org/10.3390%2Fnu14214651
Kramers BJ, Koorevaar IW, Drenth JPH, de Fijter JW, Gomes Neto A, Peters DJM, et al. Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease. Kidney Int. 2020;98(4):989-98. https://doi.org/10.1016/j.kint.2020.04.053
Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, et al. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int. 2017;91(2):493-500. https://doi.org/10.1016/j.kint.2016.10.018
McBride L, Wilkinson C, Jesudason S. Management of autosomal dominant polycystic kidney disease (ADPKD) during pregnancy: risks and challenges. Int J Womens Health. 2020;12:409-22. https://doi.org/10.2147%2FIJWH.S204997
Bulent Gul C, Yildiz A, Sag S, Oruc A, Ersoy A, Gullulu S. The effect of smoking on endothelial dysfunction in autosomal dominant polycystic kidney disease patients with preserved renal function. Ren Fail. 2021;43(1):1124-9. https://doi.org/10.1080/0886022x.2021.1949348
Shoaf SE, Ouyang J, Sergeyeva O, Estilo A, Li H, Leung D. A post hoc analysis of statin use in tolvaptán autosomal dominant polycystic kidney disease pivotal trials. Clin J Am Soc Nephrol. 2020;15(5):643-50. https://doi.org/10.2215/cjn.08170719
Kim K, Trott JF, Gao G, Chapman A, Weiss RH. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course. BMC Nephrol. 2019;20(1):66. https://doi.org/10.1186/s12882-019-1249-6
Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2267-76. https://doi.org/10.1056/nejmoa1402686
Zhou JX, Torres VE. Autosomal dominant polycystic kidney disease therapies on the horizon. Adv Kidney Dis Health. 2023;30(3):245-60. https://doi.org/10.1053/j.akdh.2023.01.003
Horie S, Muto S, Kawano H, Okada T, Shibasaki Y, Nakajima K, et al. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptán treatment in patients with autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2021;25(5):467-78. https://doi.org/10.1007%2Fs10157-020-02009-0
Nakatani D, Sakata Y, Suna S, Usami M, Matsumoto S, Shimizu M, et al. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J. 2013;77(2):439-46. https://doi.org/10.1253/circj.cj-11-1059
Mochizuki T, Muto S, Miyake M, Tanaka T, Wang W. Safety and efficacy of Tolvaptán in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance. Clin Exp Nephrol. 2021;25(11):1231-9. https://doi.org/10.1007/s10157-021-02100-0
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptán in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2018;33(3):477-89. https://doi.org/10.1093/ndt/gfx043
Lu J, Xu W, Gong L, Xu M, Tang W, Jiang W, et al. Efficacy and safety of tolvaptán versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis. Int Urol Nephrol. 2022;55(3):631-40. https://doi.org/10.1007/s11255-022-03353-8
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptán in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930-42. https://doi.org/10.1056/nejmoa1710030
Chebib FT, Zhou X, Garbinsky D, Davenport E, Nunna S, Oberdhan D, et al. Tolvaptán and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: a pooled analysis of randomized clinical trials and observational studies. Kidney Med. 2023;5(6):100639. https://doi.org/10.1016/j.xkme.2023.100639
Li X, Li W, Li Y, Dong C, Zhu P. The safety and efficacy of tolvaptán in the treatment of patients with autosomal dominant polycystic kidney disease: a systematic review and meta-analysis. Nefrologia (Engl Ed). 2023;43(6):731-41. https://doi.org/10.1016/j.nefroe.2023.04.002
Muto S, Okada T, Yasuda M, Tsubouchi H, Nakajima K, Horie S. Long-term safety profile of tolvaptán in autosomal dominant polycystic kidney disease patients: TEMPO extension Japan trial. Drug Healthc Patient Saf. 2017;9:93-104. https://doi.org/10.2147/dhps.s142825
Higashihara E, Nutahara K, Itoh M, Okegawa T, Tambo M, Yamaguchi T, et al. Long-term outcomes of longitudinal efficacy study with tolvaptán in ADPKD. Kidney Int Rep. 2022;7(2):270-81. https://doi.org/10.1016%2Fj.ekir.2021.11.034
Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, et al. Recommendations for the use of tolvaptán in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016;31(3):337-48. https://doi.org/10.1093/ndt/gfv456
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptán in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407-18. https://doi.org/10.1056/nejmoa1205511
Devuyst O, Chapman AB, Shoaf SE, Czerwiec FS, Blais JD. Tolerability of aquaretic-related symptoms following tolvaptán for autosomal dominant polycystic kidney disease: results from TEMPO 3:4. Kidney Int Rep. 2017;2(6):1132-40. https://doi.org/10.1016/j.ekir.2017.07.004
Anderegg MA, Dhayat NA, Sommer G, Semmo M, Huynh-Do U, Vogt B, et al. Quality of life in autosomal dominant polycystic kidney disease patients treated with tolvaptán. Kidney Med. 2020;2(2):162-71. https://doi.org/10.1016/j.xkme.2019.11.008
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Lee J, et al. Multicenter study of long-term safety of tolvaptán in later-stage autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2020;16(1):48-58. https://doi.org/10.2215/cjn.10250620
Merino Bueno MDC, Sango Merino C, Gallardo Pérez A, Rojo Alba S, Ruiz Zorrilla C, de la Torre Fernández MA, et al. Hepatotoxicity induced by tolvaptán: a case report. Nefrologia (Engl Ed). 2022;42(6):737-8. https://doi.org/10.1016/j.nefroe.2021.11.017
Alpers DH, Lewis JH, Hunt CM, Freston JW, Torres VE, Li H, et al. Clinical pattern of tolvaptán-associated liver injury in trial participants with autosomal dominant polycystic kidney disease (ADPKD): an analysis of pivotal clinical trials. Am J Kidney Dis. 2023;81(3):281-293.e1. https://doi.org/10.1053/j.ajkd.2022.08.012
Kramers BJ, van Gastel MDA, Meijer E, Gansevoort RT. Case report: a thiazide diuretic to treat polyuria induced by tolvaptán. BMC Nephrol. 2018;19(1):157. https://doi.org/10.1186/s12882-018-0957-7
Sans-Atxer L, Joly D. Tolvaptán in the treatment of autosomal dominant polycystic kidney disease: Patient selection and special considerations. Int J Nephrol Renovasc Dis. 2018;11:41-51. https://doi.org/10.2147/ijnrd.s125942
Thomas M, Franca Gois PH, Butcher BE, Ta MHT, Van Wyk GW. Treatment persistence to tolvaptán in patients with autosomal dominant polycystic kidney disease: a secondary use of data analysis of patients in the IMADJIN® dataset. BMC Nephrol. 2021;22(1):400. https://doi.org/10.1186/s12882-021-02607-4
Tsukamoto S, Urate S, Yamada T, Azushima K, Yamaji T, Kinguchi S, et al. Comparative efficacy of pharmacological treatments for adults with autosomal dominant polycystic kidney disease: a systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol. 2022;13:885457. https://doi.org/10.3389/fphar.2022.885457
Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet. 2013;382(9903):1485-95. https://doi.org/10.1016/s0140-6736(13)61407-5
Meijer E, Visser FW, van Aerts RMM, Blijdorp CJ, Casteleijn NF, D’Agnolo HMA, et al. Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial. JAMA. 2018;320(19):2010-9. https://doi.org/10.1001/jama.2018.15870
Trillini M, Caroli A, Perico N, Remuzzi A, Brambilla P, Villa G, et al. Effects of octreotide-long-acting release added-on tolvaptán in patients with autosomal dominant polycystic kidney disease: pilot, randomized, placebo-controlled, cross-over trial. Clin J Am Soc Nephrol. 2023;18(2):223-33. https://doi.org/10.2215/cjn.0000000000000049
Higashihara E, Nutahara K, Okegawa T, Tanbo M, Mori H, Miyazaki I, et al. Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan. Clin Exp Nephrol. 2015;19(4):746-52. https://doi.org/10.1007/s10157-014-1047-1
Ruggenenti P, Gentile G, Perico N, Perna A, Barcella L, Trillini M, et al. Effect of sirolimus on disease progression in patients with autosomal dominant polycystic kidney disease and CKD stages 3b-4. Clin J Am Soc Nephrol. 2016;11(5):785-94. https://doi.org/10.2215/cjn.09900915
He Q, Lin C, Ji S, Chen J. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials. Am J Med Sci. 2012;344(6):491-7. https://doi.org/10.1097/maj.0b013e318256754f
Perrone RD, Abebe KZ, Watnick TJ, Althouse AD, Hallows KR, Lalama CM, et al. Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). Kidney Int. 2021;100(3):684-96. https://doi.org/10.1016/j.kint.2021.06.013
Seliger SL, Abebe KZ, Hallows KR, Miskulin DC, Perrone RD, Watnick T, et al. A Randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease. Am J Nephrol. 2018;47(5):352-60. https://doi.org/10.1159/000488807
Kramers BJ, Koorevaar IW, van Gastel MDA, van Goor H, Hallows KR, Heerspink HL, et al. Effects of hydrochlorothiazide and metformin on aquaresis and nephroprotection by a vasopressin V2 receptor antagonist in ADPKD: a randomized crossover trial. Clin J Am Soc Nephrol. 2022;17(4):507-17. https://doi.org/10.2215/cjn.11260821
Gansevoort RT, Hariri A, Minini P, Ahn C, Chapman AB, Horie S, et al. Venglustat, a novel glucosylceramide synthase inhibitor, in patients at risk of rapidly progressing ADPKD: primary results of a double-blind, placebo-controlled, phase 2/3 randomized clinical trial. Am J Kidney Dis. 2023;81(5):517-27.e1. https://doi.org/10.1053/j.ajkd.2022.10.016
Perrone RD, Hariri A, Minini P, Ahn C, Chapman AB, Horie S, et al. The STAGED-PKD 2-Stage adaptive study with a patient enrichment strategy and treatment effect modeling for improved study design efficiency in patients with ADPKD. Kidney Med. 2022;4(10):100538. https://doi.org/10.1016/j.xkme.2022.100538
Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287-301. https://doi.org/10.1016/s0140-6736(07)60601-1
Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant. 2017;32(8):1356-63. https://doi.org/10.1093/ndt/gfw240
Budhram B, Akbari A, Brown P, Biyani M, Knoll G, Zimmerman D, et al. End-Stage kidney disease in patients with autosomal dominant polycystic kidney disease: a 12-year study based on the Canadian organ replacement registry. Can J Kidney Health Dis. 2018;5:2054358118778568. https://doi.org/10.1177/2054358118778568
Sigogne M, Kanagaratnam L, Mora C, Pierre M, Petrache A, Marcus C, et al. Identification of the factors associated with intraperitoneal pressure in ADPKD patients treated with peritoneal dialysis. Kidney Int Rep. 2020;5(7):1007-13. https://doi.org/10.1016%2Fj.ekir.2020.04.012
Dupont V, Kanagaratnam L, Sigogne M, Bechade C, Lobbedez T, Portoles J, et al. Outcome of polycystic kidney disease patients on peritoneal dialysis: systematic review of literature and meta-analysis. PLoS One. 2018;13(5):e0196769. https://doi.org/10.1371/journal.pone.0196769
Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009;76(2):149-68. https://doi.org/10.1038/ki.2009.128
Chebib FT, Prieto M, Jung Y, Irazabal MV, Kremers WK, Dean PG, et al. Native nephrectomy in renal transplant recipients with autosomal dominant polycystic kidney disease. Transplant Direct. 2015;1(10):e43. https://doi.org/10.1097/txd.0000000000000554
Xu J, D’Souza K, Lau NS, Leslie S, Lee T, Yao J, et al. Staged versus concurrent native nephrectomy and renal transplantation in patients with autosomal dominant polycystic kidney disease: a systematic review. Transplant Rev (Orlando). 2022;36(1):100652. https://doi.org/10.1016/j.trre.2021.100652
Ye W, Voss MD, Athreya S. Volume reduction in enlarged kidneys in autosomal dominant polycystic kidney disease (ADPKD) prior to renal transplant with transcatheter arterial embolization (TAE): a systematic review and meta-analysis. Cardiovasc Intervent Radiol. 2018;41(6):828-34. https://doi.org/10.1007/s00270-018-1890-7
Han JH, Jeong SH, Yuk HD, Ku JH, Kwak C, Kim HH, et al. Safety and feasibility of synchronous unilateral nephrectomy and contralateral heminephrectomy for extremely severe autosomal dominant polycystic kidney disease: techniques and outcome. Investig Clin Urol. 2022;63(3):341-9. https://doi.org/10.4111/icu.20210461
Lanktree MB, Haghighi A, di Bari I, Song X, Pei Y. Insights into autosomal dominant polycystic kidney disease from genetic studies. Clin J Am Soc Nephrol. 2021;16(5):790-9. https://doi.org/10.2215/cjn.02320220
Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet. 1994;343(8901):824-7. https://doi.org/10.1016/s0140-6736(94)92026-5
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.